FSD Pharma (CSE:HUGE) CCO Michael Ash outlines the company’s joint venture partnership with Auxly Cannabis Group (TSXV:XLY) and its recent record-breaking trade volume on the CSE.

In the interview below, Ash also provides an update on the company’s Ontario-based subsidiary, FV Pharma, and how its extensive growing facilities will be able to meet the demands of the legalized cannabis market. He also lays out the upcoming catalysts for the medicinal cannabis market.

Below is a transcript of our interview with FSD Pharma CCO Michael Ash. It has been edited for clarity and brevity.

Investing News Network: Please give our investor audience an overview of FSD Pharma and its wholly owned subsidiary, FV Pharma. 

FSD Pharma CCO Michael Ash: FSD Pharma owns the 620,000-square-foot former Kraft plant in Cobourg, Ontario, about an hour east of Toronto. As part of our joint venture project, Auxly has committed $55 million to help us retrofit 220,000 square feet of the plant. In the meanwhile, we have 25,000 square feet of growing space currently. Aside from our indoor hydroponic space, we have an additional 40 acres primed for development of our total 70 acres, which gives us ample space to supply hundreds of millions of grams of product.

INN: Tell us about your joint venture partnership with Auxly. What is the significance of the recently announced update for the project?

MA: Auxly’s $55-million investment with FSD Pharma shows its belief in our capacity to provide product and shows a commitment to the industry. We know that it will be a multibillion-dollar industry and we’re excited about the possibilities. 

INN: What opportunities will stem from running a cannabis cultivation and processing facility of such magnitude?

MA: The companies that will be able to meet the demands of the market are the ones that will survive. We believe that there will be shortages of recreational and medical cannabis, and we’ve positioned ourselves to be able to meet the demands of both markets. We are going to primarily focus on the medical cannabis market because we believe that the recreational market will be commodity based.

INN: What other investments and partnerships has FSD Pharma entered into recently? How does that tie into the company’s business model?

MA: We believe wholeheartedly in the medical applications of cannabis, and have recently entered into a deal with Canntab Therapeutics (CSE:PILL). Our deal with Canntab will supply tablets and capsules to the consumer market and has huge potential for growth, particularly as the cannabinoid market grows.

The vitamin and mineral supplement market over the last 30 years has seen enormous growth, and supplement producers are able to make various claims about their products, such as that they help with sleep, joint pain or can curve appetite. Likewise, cannabinoid research is coming to the point where claims can be made, particularly in that it can help with sleep, anxiety and pain. The fact that the FDA approved the first cannabinoid-based prescription for epilepsy a couple weeks ago is also an indication for where the over-the-counter cannabinoid prescription market will be going.

INN: FSD Pharma has been breaking a number trading volume records since being listed on the CSE in May 2018. What does this mean for the company and for investors?

MA: The trading volume says a lot about the interest in our company. We’re still a micro-cap company, but the deals we have been working on and the opportunities that exist for us will continue to generate volume and interest from retail investors.

CEO interviews are part of investor education campaigns for clients advertising on the Investing News Network. Important news is contextualized by CEOs, and the resulting interviews are disseminated to the Investing News Network audience because they have value to market watchers.

The Investing News Network interviews a CEO for an understanding of their perspective on the company, the investment potential of the company and market news related to the company. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities.

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less